Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1038/nrcardio.2013.117

http://scihub22266oqcxt.onion/10.1038/nrcardio.2013.117
suck pdf from google scholar
23959229!ä!23959229

suck abstract from ncbi


Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid23959229      Nat+Rev+Cardiol 2013 ; 10 (10): 560-70
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Pharmacotherapies for lipid modification: beyond the statins #MMPMID23959229
  • Gotto AM Jr; Moon JE
  • Nat Rev Cardiol 2013[Oct]; 10 (10): 560-70 PMID23959229show ga
  • The widespread clinical use of statins has contributed to significant reductions in the rate of cardiovascular morbidity and mortality over the past 3 decades, and statins are considered first-line therapy for the prevention and treatment of atherosclerotic vascular disease. Nevertheless, various other lipid-lowering agents can provide clinical benefit by supplementing or augmenting statin therapy in patients with severe hypercholesterolaemia or mixed dyslipidaemia, or by providing an alternative for patients who are intolerant to statins. Bile acid resins and niacin were prescribed for lipid modification for years before the introduction of the statins, and new data continue to emerge regarding their use in different patient groups and for specific conditions. Ezetimibe can be appropriate for patients whose primary lipid abnormality is an elevated LDL-cholesterol level, whereas the fibrates seem to be most beneficial in patients with low levels of HDL cholesterol and elevated triglycerides. At the end of 2012 and the beginning of 2013, the first microsomal triglyceride transfer protein inhibitor, lomitapide, and the first antisense therapy to target apolipoprotein B, mipomersen, were approved for the treatment of individuals with extremely elevated LDL-cholesterol levels caused by homozygous familial hypercholesterolaemia. Although two agents in the experimental class of cholesteryl ester transfer protein inhibitors have failed to show a benefit in clinical trials, newer drugs in this class could provide an additional strategy to address residual cardiovascular risk in patients treated with statins.
  • |Animals[MESH]
  • |Biomarkers/blood[MESH]
  • |Cardiovascular Diseases/etiology/*prevention & control[MESH]
  • |Dyslipidemias/blood/complications/diagnosis/*drug therapy[MESH]
  • |Humans[MESH]
  • |Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use[MESH]
  • |Hypolipidemic Agents/adverse effects/*therapeutic use[MESH]
  • |Lipid Metabolism/drug effects[MESH]
  • |Lipids/*blood[MESH]
  • |Risk Factors[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box